COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #223 of 237
12/29 Late treatment study
Güner et al., Journal of Infection and Public Health, doi:10.1016/j.jiph.2020.12.017 (Peer Reviewed)
Comparing ICU Admission Rates of Mild/Moderate COVID-19 Patients Treated with Hydroxychloroquine, Favipiravir, and Hydroxychloroquine plus Favipiravir
Source   PDF   Share   Tweet
Retrospective 824 hospitalized patients in Turkey showing lower ICU admission for HCQ vs. favipiravir.

Güner et al., 12/29/2020, retrospective, Turkey, Middle East, peer-reviewed, 23 authors.
risk of ICU admission, 77.3% lower, RR 0.23, p = 0.16, treatment 604, control 100, IPTW multivariate analysis.
Details of all 237 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit